Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

AcademySystematic Review

How-to guideJBI 2020–2026, PRISMA-ScR 2018

How to Write a Scoping Review: Step-by-Step from Protocol to PRISMA-ScR (JBI Method)

Seven practical steps based on JBI guidance, from the PCC question and registered protocol to data charting, evidence maps and PRISMA-ScR reporting, with an illustrative worked example.

Dr. CharlieSenior Medical WriterPublishedReading time12 minutesSources19
  • Scoping review
  • JBI
  • PRISMA-ScR
  • Evidence synthesis

At a glanceSystematic Review

Method
JBI guidance (nine stages)
Question
PCC: Population, Concept, Context
Registration
OSF, INPLASY or published protocol; not PROSPERO
Reporting
PRISMA-ScR: 20 essential + 2 optional items

Explore scoping review servicesDiscuss your project

Quick answer

  • A scoping review maps the evidence, concepts and gaps on a topic; it does not test effectiveness or pool results.
  • Frame the question with PCC, then register a protocol on OSF or INPLASY, or publish it; PROSPERO does not accept scoping reviews.
  • Run a three-step search, screen with at least two reviewers, chart only data tied to the question, and report with PRISMA-ScR.

What a Scoping Review Is

A scoping review maps the extent, range and nature of the evidence on a topic. It identifies the types of available evidence, clarifies key concepts and definitions, examines how research has been conducted and highlights knowledge gaps12. It does not usually answer a narrow effectiveness question, and it does not pool results into a summary estimate.

The method has a clear lineage. Arksey and O’Malley proposed the first framework in 20053, Levac and colleagues refined each stage in 20104, and the JBI Scoping Review Methodology Group has since published the guidance most journals now expect15. Reporting follows a separate guideline, PRISMA-ScR6.

This guide sets out seven practical steps based on JBI guidance, with one illustrative worked example running throughout. JBI’s protocol and results guidance describes nine stages; Table 1 shows how the two line up78.

Table 1. Seven practical steps in this guide mapped to the nine JBI stages.

Step in this guideJBI stage(s)
1. Define the PCC question1. Define the objective and review question; 2. Develop inclusion criteria aligned with the objective and question
2. Write and register the protocol3. Describe the planned approach to evidence searching, selection, extraction and presentation (the protocol also records stages 1 and 2)
3. Search comprehensively4. Search for the evidence
4. Select sources of evidence5. Select the evidence
5. Chart the data6. Extract the evidence
6. Analyse and present the evidence map7. Analyse the evidence; 8. Present the results
7. Report with PRISMA-ScR9. Summarise the evidence in relation to the purpose, draw conclusions and note implications

Scoping Review or Systematic Review?

Choose the review type from the question, not the workload. A scoping review is not a quicker or easier systematic review; it answers a different kind of question with equally rigorous and transparent methods2.

Table 2. Scoping review versus systematic review.

FeatureScoping reviewSystematic review
PurposeMap evidence, concepts, research methods and gapsAnswer a focused question, for example on effectiveness, accuracy or prognosis
Question frameworkPCC (Population, Concept, Context)Usually PICO or a variant
Critical appraisalGenerally not done; if done, justify it and do not use it to exclude sourcesExpected (risk of bias assessment)
SynthesisDescriptive: frequency counts, tables, charts, basic qualitative content analysisMeta-analysis or structured narrative synthesis
Protocol guidanceJBI scoping protocol guidancePRISMA-P
Protocol registrationOSF Registries, INPLASY or a published protocol; not PROSPEROPROSPERO (if at least one health-related outcome), OSF or INPLASY
Reporting guidelinePRISMA-ScRPRISMA 2020

Sources: JBI guidance17, PRISMA-ScR6 and PRISMA-P9.

When not to do a scoping review

Munn and colleagues list appropriate indications: identifying the types of evidence in a field, clarifying concepts, examining how research is conducted, identifying key characteristics related to a concept, acting as a precursor to a systematic review, and identifying knowledge gaps2. A scoping review is the wrong choice when:

  • you need to tell clinicians or policymakers whether an intervention works, or how well a test performs; use a systematic review;
  • you plan to judge the certainty of evidence or make recommendations, which needs appraisal of the included studies;
  • the topic is already well mapped and a recent scoping review exists, unless you can justify an update.

Our review type and protocol case studies show how teams have made this choice in practice.

Step 1: Define the PCC Question

JBI recommends framing the review question and the eligibility criteria with PCC: Population, Concept and Context1. The question should be broad enough to map a field but specific enough to set clear boundaries.

Table 3. PCC framework with an illustrative worked example.

ElementIllustrative worked example
PopulationAdults aged 65 years and over living with multimorbidity (two or more long-term conditions)
ConceptDigital health interventions for medication management: smartphone apps, telemonitoring and smart dispensers
ContextPrimary care and home settings in high-income countries
Review questionWhat digital medication-management interventions have been evaluated for older adults with multimorbidity in primary care and home settings, and which outcomes have been measured?

Turn PCC into eligibility criteria

The protocol then converts each PCC element into explicit criteria and adds the types of evidence sources, languages and dates you will consider. Justify every limit7.

Table 4. From PCC to eligibility criteria (illustrative).

CriterionIncludeExclude
PopulationMean or median age 65 years or over, or separate data for this group; two or more long-term conditionsSingle-condition populations; mixed-age samples without separate data
ConceptDigital tools whose main purpose is supporting medication managementDigital tools whose main purpose is not medication management (for example general telehealth without a medication component)
ContextPrimary care or home settings in high-income countriesInpatient-only or long-term residential care
Types of evidence sourcePrimary studies of any design, systematic and scoping reviews (for reference checking), relevant grey literature such as evaluation reportsEditorials, commentaries and conference abstracts without usable detail
LanguageAny language where translation is feasible; state how translation will be handledSources in languages the team cannot translate (excluded and reported as a limitation)
DatesFrom 2000 onwards (illustrative; justify the start year in the protocol)Sources published before 2000

Planning a scoping review?

Pubrica’s scoping review team supports PCC question and protocol development, OSF or INPLASY registration, search design with PRESS peer review, duplicate screening, data charting, evidence gap maps and PRISMA-ScR reporting. Review authors keep ownership of and accountability for the review, and no provider can guarantee acceptance.

Step 2: Write and Register the Scoping Review Protocol

A protocol written before the search reduces the risk of decisions being driven by what you find. JBI guidance lists what a scoping review protocol should contain: title, objectives and question, the PCC-based eligibility criteria, types of evidence sources, search strategy, source selection process, data charting items, analysis and presentation plans, and any planned consultation7. PRISMA-P was written for systematic review protocols, so use the JBI guidance for a scoping protocol79.

Where to register

Table 5. Registration routes for a scoping review protocol.

RouteKey points
OSF RegistriesUse the Generalized Systematic Review Registration form, which is designed to cover scoping reviews; all project admins must approve, or the registration is approved automatically after 48 hours; a DOI is minted when the registration is public; embargoes of up to four years are possible; later changes are logged as updates with a justification
INPLASYHas a dedicated scoping review form and is funded by author fees: a 2023 description reported US$20 to register and US$9 per update (June 2023); check the current fee before submitting
Published protocolJournals such as JBI Evidence Synthesis publish scoping review protocols after peer review
PROSPERONot an option: PROSPERO excludes scoping reviews, mapping reviews and evidence maps

Sources: OSF1011, INPLASY1213 and PROSPERO14.

Register ideally before screening starts. Report the registration or protocol details under PRISMA-ScR item 56. Good practice is also to describe later changes as protocol deviations with reasons; the PRISMA-ScR update team has proposed this as a new item15. For a step-by-step comparison of the registries, see our guide to PROSPERO vs OSF vs INPLASY.

JBI recommends a three-step search161:

  1. an initial limited search of at least two appropriate databases, then analysis of the words in titles and abstracts and the index terms used to describe relevant records;
  2. a full search across all included databases and sources, using every identified keyword and index term, adapted to each database;
  3. screening the reference lists of included sources for additional evidence.

Search the Population and Concept. A common approach is to apply Context, such as setting or country, at screening rather than in the search, because setting is poorly indexed and restricting it in the search risks missing relevant records. The illustrative MEDLINE (Ovid) strategy below shows the structure for the worked example; it is not a validated or complete strategy.

1. exp Aged/ OR (older adult* OR elderly OR geriatric* OR aged 65).ti,ab.
2. Multimorbidity/ OR (multimorbid* OR multi-morbid* OR multiple chronic condition* OR multiple long-term condition*).ti,ab.
3. Telemedicine/ OR Mobile Applications/ OR (mHealth OR mobile app* OR smartphone* OR telemonitor* OR telehealth OR smart dispens* OR electronic pill box*).ti,ab.
4. Medication Therapy Management/ OR (medication management OR medicines management OR medication reminder* OR pill reminder* OR medication support OR polypharmacy management).ti,ab.
5. 1 AND 2 AND 3 AND 4

Line 4 is part of the Concept: it captures interventions that manage medicines. Do not add outcomes such as adherence as a search block, because a scoping review aims to find every relevant source, whichever outcomes it reports.

Ask an information specialist to peer review the strategy with the PRESS 2015 checklist before you translate it to other databases17; see our PRESS checklist guide. Add grey literature and trial registers where they are likely to hold relevant sources.

Record what you search as you go, because PRISMA-ScR splits it across two items6:

  • Item 7, information sources: every database and source with dates of coverage, contact with authors to identify more sources, and the date the most recent search was run.
  • Item 8, search: the full electronic search strategy for at least one database, including any limits used, so it could be repeated.

The PRISMA-S guide covers search reporting in more detail.

Step 4: Select Sources of Evidence

Screen titles and abstracts, then full texts, against the protocol criteria. Use at least two reviewers working independently, and resolve disagreements by discussion or with a third reviewer1.

Calibrate first. The 2020 version of the JBI Manual chapter suggests a pilot in which the team screens a random sample of 25 titles and abstracts, discusses discrepancies and refines the criteria, and starts full screening once agreement reaches 75% or more16. Levac and colleagues recommend an iterative team approach, meeting at the start, middle and end of screening to discuss uncertainties4.

Screening software such as Covidence, Rayyan or EPPI-Reviewer can manage deduplication, blinding between reviewers and conflict resolution. Choose a tool your team can access and name it in the methods.

Record reasons for excluding full texts. PRISMA-ScR item 14 asks for the numbers of sources screened, assessed for eligibility and included, with reasons for exclusion at each stage, ideally in a flow diagram6. There is no separate PRISMA-ScR flow template, so authors usually adapt the PRISMA 2020 flow diagram, relabelling “studies” as “sources of evidence” where appropriate18. Our PRISMA 2020 flow diagram guide explains each box.

Step 5: Chart the Data

Data charting is the scoping review term for data extraction. Build the charting form from the review question and PCC elements, and chart only items that help answer the question8. Charting effect sizes or detailed results is usually unnecessary, because the review maps the evidence rather than evaluating it8.

Pilot the form: two or more reviewers chart a few sources independently, compare results and refine the form, then continue charting iteratively, recording every change to the form164. PRISMA-ScR asks you to describe the charting process, including any process for obtaining and confirming data from investigators (item 10), and to list the variables charted (item 11)6.

Table 6. Illustrative data charting form for the worked example (fictional entries).

Charting itemFictional example entry
Citation, year, countryAuthor et al., 2023, Germany
Type of evidence source and designPilot randomised controlled trial
Population detailsn = 120; mean age 78 years; three or more long-term conditions
Intervention type (Concept)Smartphone app with reminders and a pharmacist dashboard
Setting (Context)Primary care practices with home use
Outcome domains measuredAdherence (pill count), usability (System Usability Scale), hospital admissions
Relevance to the review questionAdds an app-based intervention measuring usability and admissions

Critical appraisal

JBI states that scoping reviews generally do not include critical appraisal of the included sources. If you do appraise them, for example because stakeholders need it, justify the decision in the protocol and do not use appraisal results to exclude sources116. In PRISMA-ScR, the two items on critical appraisal (items 12 and 16) are optional6.

Step 6: Analyse and Present the Evidence Map

Scoping reviews analyse evidence descriptively. Use frequency counts of source characteristics and concepts, and, where helpful, basic qualitative content analysis that codes and groups text into categories8. Present the results in formats that match the question8:

  • Tables: characteristics of included sources and the concepts they cover.
  • Charts: sources by year, country, design or intervention type.
  • Evidence gap maps: a matrix of, for example, intervention types against outcome domains, showing where evidence is dense or missing.
  • Narrative summary: text explaining how the visuals answer the review question.

Table 7 shows an evidence gap map for the worked example, using the three intervention types defined in the PCC. The numbers are fictional and for illustration only.

Table 7. Illustrative evidence gap map: number of sources by intervention type and outcome domain (fictional data).

Intervention typeAdherenceUsabilityHospital admissionsQuality of life
Smartphone app141142
Telemonitoring8563
Smart dispenser9620

In this fictional map, quality of life is rarely measured, and no source evaluates it for smart dispensers. That is a gap to report, not evidence that the interventions do or do not improve quality of life.

Optional stage: consultation

Arksey and O’Malley included consultation with stakeholders as an optional sixth stage3. Levac and colleagues recommend making it a required knowledge-translation component, for example asking patients, clinicians or policymakers to comment on the preliminary findings and gaps4. If you plan consultation, describe who, when and how in the protocol7.

Step 7: Report with PRISMA-ScR

Report the review with PRISMA-ScR, which has 20 essential items and two optional items on critical appraisal6. It was adapted from the 2009 PRISMA statement: five items were removed and two were made optional. Items that journal reviewers commonly query include:

  • Item 5: protocol and registration details.
  • Items 7 and 8: information sources and the full search for at least one database.
  • Item 14: selection numbers with reasons for exclusion, ideally as a flow diagram.
  • Item 19: a summary of evidence that links results to the questions and objectives and considers relevance to key groups.
  • Item 22: sources of funding for the included sources of evidence as well as for the review, and the role of the funders.

Draw conclusions that answer the review objectives and state implications for research and, where relevant, practice; scoping reviews should not make graded clinical recommendations17.

Provide the completed checklist, the search strategy and the charting form as supplementary files. Avoid language that implies effectiveness, such as “the intervention improves adherence”; write instead that a given number of sources measured adherence.

An update of PRISMA-ScR is in development: the team has published a protocol and a scoping review identifying candidate new items, which will go to a Delphi survey1915. Until a new version is published, the 2018 checklist remains the current standard. Our PRISMA-ScR checklist guide explains every item.

Before you submit a scoping review

  • The review question is framed with PCC, and the reason for choosing a scoping review is stated.
  • The protocol was registered on OSF or INPLASY, or published, and deviations are reported.
  • The search used at least two databases in the initial step, was peer reviewed, and is reported under items 7 and 8.
  • At least two reviewers screened independently after a calibration pilot.
  • The charting form was piloted and charts only items linked to the question.
  • Any critical appraisal is justified and was not used to exclude sources.
  • Results are descriptive, with no claims of effectiveness.
  • The PRISMA-ScR checklist and an adapted PRISMA 2020 flow diagram are included.

Conclusion

Writing a good scoping review comes down to method: a clear PCC question, a registered protocol, a peer-reviewed three-step search, calibrated screening by at least two reviewers, focused data charting and a descriptive evidence map reported with PRISMA-ScR. Following JBI guidance keeps the review transparent and reproducible, and keeps it clearly distinct from a systematic review.

For quick answers on PRISMA-ScR, registration and German guideline work, see our scoping review Q&A. If the review will feed a German clinical guideline, read our overview of AWMF S3 guideline evidence review requirements.

Pubrica team verdict

A scoping review earns trust through transparent method, not through critical appraisal or pooled estimates: a registered protocol, a reproducible search and focused charting matter most.

Frequently asked questions

A scoping review maps the evidence on a broad topic, including concepts, research methods and gaps, and usually skips critical appraisal. A systematic review answers a focused question, appraises the included studies and often pools results.

No. PROSPERO excludes scoping reviews14. Register the protocol on OSF Registries using the generalized registration form, on INPLASY using its scoping review form, or publish it in a journal such as JBI Evidence Synthesis.

No. JBI states that scoping reviews generally do not include it. If you do appraise sources, justify it and do not use the results to exclude sources. PRISMA-ScR treats the related items 12 and 16 as optional.

JBI recommends PCC: Population, Concept and Context. It shapes both the review question and the eligibility criteria.

JBI recommends an initial limited search of at least two appropriate databases, followed by a full search of all relevant databases and sources, then reference list checking. The number depends on the topic; most health topics need several databases plus grey literature.

JBI guidance expects at least two reviewers to screen sources independently, after a pilot to calibrate the eligibility criteria. Charting is also best piloted by two or more reviewers.

PRISMA-ScR item 14 asks for selection numbers with reasons for exclusion, ideally in a flow diagram. There is no separate PRISMA-ScR template, so authors usually adapt the PRISMA 2020 diagram.

Use the JBI guidance and reporting items for scoping review protocols published by Peters and colleagues in 2022. PRISMA-P was designed for systematic review protocols.

Yes. An update is in development, with a published protocol and a scoping review of candidate items. Until a new version is published, use the 2018 PRISMA-ScR checklist.

Sources

Sources were checked on 22 November 2026. Requirements and guidance may change after that date; confirm the current version with the issuing body.

  1. 1Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119-26. https://doi.org/10.11124/JBIES-20-00167
  2. 2Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143. https://doi.org/10.1186/s12874-018-0611-x
  3. 3Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19-32. https://doi.org/10.1080/1364557032000119616
  4. 4Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. https://doi.org/10.1186/1748-5908-5-69
  5. 5Pollock D, Peters MDJ, Tricco AC, Munn Z, Jia RM, Alexander L, et al. Scoping reviews (2026). In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI Manual for Evidence Synthesis. JBI; 2024 [cited 2026 Nov 22]. Available from: https://doi.org/10.46658/JBIMES-24-09
  6. 6Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-73. https://doi.org/10.7326/M18-0850
  7. 7Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, et al. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20(4):953-68. https://doi.org/10.11124/JBIES-21-00242
  8. 8Pollock D, Peters MDJ, Khalil H, McInerney P, Alexander L, Tricco AC, et al. Recommendations for the extraction, analysis, and presentation of results in scoping reviews. JBI Evid Synth. 2023;21(3):520-32. https://doi.org/10.11124/JBIES-22-00123
  9. 9Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https://doi.org/10.1186/2046-4053-4-1
  10. 10van den Akker OR, Peters GY, Bakker CJ, Carlsson R, Coles NA, Corker KS, et al. Increasing the transparency of systematic reviews: presenting a generalized registration form. Syst Rev. 2023;12(1):170. https://doi.org/10.1186/s13643-023-02281-7
  11. 11Center for Open Science. Registration and preregistration FAQs [Internet]. Charlottesville (VA): OSF Support; [cited 2026 Nov 22]. Available from: https://help.osf.io/category/549-registration-and-preregistration-faqs
  12. 12INPLASY. International Platform of Registered Systematic Review and Meta-analysis Protocols [Internet]. [cited 2026 Nov 22]. Available from: https://inplasy.com/
  13. 13Canellas JVDS, Ritto FG, Rodolico A, Aguglia E, Fernandes GVO, Figueredo CMDS, et al. The international platform of registered systematic review and meta-analysis protocols (INPLASY) at 3 years. Front Res Metr Anal. 2023;8:1135853. https://doi.org/10.3389/frma.2023.1135853
  14. 14Centre for Reviews and Dissemination, University of York. PROSPERO: international prospective register of systematic reviews [Internet]. York: University of York; [cited 2026 Nov 22]. Available from: https://www.crd.york.ac.uk/prospero/
  15. 15Tricco AC, Robinson E, Straus SE, Colquhoun H, Godfrey CM, Moher D, et al. Updating the PRISMA reporting guideline for scoping reviews: a scoping review. J Clin Epidemiol. 2026;196:112314. https://doi.org/10.1016/j.jclinepi.2026.112314
  16. 16Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: Scoping reviews (2020 version). In: Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis. JBI; 2020. Available from: https://doi.org/10.46658/JBIMES-20-12
  17. 17McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40-6. https://doi.org/10.1016/j.jclinepi.2016.01.021
  18. 18Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
  19. 19Veroniki AA, Hutton B, Stevens A, McKenzie JE, Page MJ, Moher D, et al. Update to the PRISMA guidelines for network meta-analyses and scoping reviews and development of guidelines for rapid reviews: a scoping review protocol. JBI Evid Synth. 2025;23(3):517-26. https://doi.org/10.11124/JBIES-24-00308

how to write a scoping reviewscoping reviewJBI methodologyPCC frameworkscoping review protocoldata charting

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation, so check its guide if it has one.

Dr. Charlie. (2026, November 22). How to Write a Scoping Review: Step-by-Step from Protocol to PRISMA-ScR (JBI Method). Pubrica. https://pubrica.com/academy/systematic-review/how-to-write-a-scoping-review/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Next steps

Planning a scoping review?

Pubrica’s scoping review team supports PCC question and protocol development, OSF or INPLASY registration, search design with PRESS peer review, duplicate screening, data charting, evidence gap maps and PRISMA-ScR reporting. Review authors keep ownership of and accountability for the review, and no provider can guarantee acceptance.

This article is general information for researchers, not legal, regulatory or funding advice. Check the current requirements of your journal, funder, ethics committee or regulator before you act on it.

More in Systematic Review

All of Academy

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.